Heart Failure Risk Reduction in Diabetes: What the Practicing Endocrinologist Should Know

Join the experts at this live webinar as they discuss leveraging the cardioprotective effects of SGLT2 inhibitors to reduce heart failure risk in your patients with type 2 diabetes.

Share

Program Content

Activities

Slides: HF Risk Reduction in T2D
Heart Failure Risk Reduction in Diabetes: What the Practicing Endocrinologist Should Know
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2021

Expires: June 06, 2022

Activities

HF Risk Reduction in T2D
Heart Failure Risk Reduction in Diabetes: What the Practicing Endocrinologist Should Know
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: June 21, 2021

Expires: June 30, 2022

Activities

HF in Patients with T2D
My Take on How SGLT2i Provide Opportunities for Cross-Specialty Collaboration in Patients With T2D and HF
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: June 22, 2021

Expires: June 21, 2022

Faculty

cover img faculity

Jennifer B Green, MD

Professor of Medicine
Division of Endocrinology
Duke Clinical Research Institute
Duke University School of Medicine
Durham, North Carolina

cover img faculity

Mikhail N. Kosiborod, MD

Professor of Medicine
Kansas City School of Medicine
University of Missouri
Consulting Cardiologist
Division of Cardiovascular Research
Department of Cardiology
Saint Lukes Mid America Heart Institute
Kansas City, Missouri

Provided by

ProCE Banner

Supporters

This activity is supported by an independent educational grant from

Boehringer Ingelheim and Eli Lilly